INVIVYD, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • March 28th, 2024 • Invivyd, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (this “Agreement”) is dated as of , 20__, and is between Invivyd, Inc., a Delaware corporation (the “Company”), and ____________ (“Indemnitee”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 28th, 2024 • Invivyd, Inc. • Biological products, (no disgnostic substances) • California
This Employment Agreement (“Agreement”) is made between Adagio Therapeutics, Inc., a Delaware corporation (the “Company”), and Peter Schmidt (the “Executive”) and is effective as of November 9, 2020 (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the offer letter between the Executive and the Company dated November 9, 2020 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.
Employment AGREEMENTEmployment Agreement • March 28th, 2024 • Invivyd, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Employment Agreement (“Agreement”) is made between Invivyd, Inc., a Delaware corporation (the “Company”), and Stacy Price (“Executive”), this 3rd day of February, 2023.
FIRST AMENDMENT TO THE EMPLOYMENT AGREEMENT OF PETER SCHMIDTEmployment Agreement • March 28th, 2024 • Invivyd, Inc. • Biological products, (no disgnostic substances)
This First Amendment to the Employment Agreement of Peter Schmidt (the “Amendment”) is entered into this 6th day of December 2022 (the “Amendment Effective Date”), by and between Peter Schmidt (the “Executive”) and Invivyd, Inc. (the “Company”).
AMENDMENT NO. 2 TO THE CELL LINE LICENSE AGREEMENTLine License Agreement • March 28th, 2024 • Invivyd, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 2 TO THE CELL LINE LICENSE AGREEMENT (this “Amendment No. 2”), effective as of March 13, 2024 (“the Amendment No. 2 Effective Date”), is entered and made by and between WuXi Biologics (Hong Kong) Limited, having an address at Flat/RM826, 8/F Ocean Centre Harbour City, 5 Canton Road TST, Hong Kong (“WuXi Biologics”), and Invivyd, Inc. having its principal place of business at 1601 Trapelo Road, Suite 178, Waltham, MA 02451 (“Licensee”). WuXi Biologics and Licensee may be referred to herein individually as a “Party” and collectively as the “Parties.”
